- Home
- ZYME vs THRM Comparison
ZYME vs THRM Comparison
Compare ZYME & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | THRM |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | 1993 |
Fundamental Metrics
Financial Performance| Metric | ZYME | THRM |
|---|---|---|
| Price | $26.58 | $35.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $28.00 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.9M | 172.0K |
| Earning Date | 11-06-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.99 |
| Revenue | $134,481,000.00 | ★ $1,468,728,000.00 |
| Revenue This Year | $65.21 | $3.56 |
| Revenue Next Year | $20.39 | $2.52 |
| P/E Ratio | ★ N/A | $35.96 |
| Revenue Growth | ★ 116.21 | N/A |
| 52 Week Low | $9.03 | $22.75 |
| 52 Week High | $28.49 | $43.99 |
Technical Indicators
Market Signals| Indicator | ZYME | THRM |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 51.62 |
| Support Level | $21.89 | $32.60 |
| Resistance Level | $28.49 | $36.62 |
| Average True Range (ATR) | 1.53 | 1.20 |
| MACD | 0.65 | -0.02 |
| Stochastic Oscillator | 84.61 | 54.45 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.